Zuckerman J M, Tunkel A R
Division of Infectious Diseases, Medical College of Pennsylvania, Philadelphia 19129.
Infect Control Hosp Epidemiol. 1994 Jun;15(6):397-410. doi: 10.1086/646938.
The azole antifungal agents represent a major advance in the management of superficial and systemic fungal infections. Itraconazole appears to have a broad spectrum of in vitro activity and is the first azole antifungal agent to have activity against Aspergillus species. Itraconazole acts primarily by impairing the synthesis of ergosterol, resulting in a defective fungal cell membrane with altered permeability and function. It is effective for a wide variety of mycotic infections and some fungal meningeal infections. Most adverse effects have been relatively minor and do not lead to discontinuation of therapy.
唑类抗真菌药物是浅表和全身性真菌感染治疗方面的一项重大进展。伊曲康唑似乎具有广泛的体外活性，是首个对曲霉菌属有活性的唑类抗真菌药物。伊曲康唑主要通过损害麦角固醇的合成起作用，导致真菌细胞膜有缺陷，通透性和功能改变。它对多种霉菌感染和一些真菌性脑膜炎感染有效。大多数不良反应相对较轻，不会导致治疗中断。
